Laurus Labs
Transitioning from an ARV API base to a diversified CDMO/CRDMO platform across small molecules, biologics and crop science, with heavy capex now monetizing.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
ARV APIs/FDF, fast-growing CDMO (small molecule + bio), gene therapy & ag-bio optionality.
CDMO order-book conversion + bio scale-up
Capex payback & ARV pricing pressure
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Laurus Labs | 18% | 20% | 17.8% | 83x |
| Divi's Laboratories | 10% | 32% | 22% | 68x |
| Neuland Laboratories | 53% | 22% | 19% | 60x |
| Suven Pharmaceuticals (now Cohance Lifesciences) | -2% | 19% | 8.4% | 83x |
| Syngene International | -5% | 29% | 10.1% | 48x |
| Granules India | 19% | 21% | 15% | 31x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • CDMO order-book conversion + bio scale-up underpins a 18% 5Y revenue CAGR.
- • Operating leverage as scale builds toward higher margins (currently 20% EBITDA).
- • Capacity already in place to support the next growth phase.
- • Capex payback & ARV pricing pressure.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Valuation at 83x P/E prices in continued execution — little margin for error.
Laurus Labs screens as a improving api franchise. With revenue of ₹5.6K Cr growing ~18% and 20% EBITDA margins, the base case is steady compounding driven by cdmo order-book conversion + bio scale-up, while watching capex payback & arv pricing pressure.
Trades at 83x P/E, 30.0x EV/EBITDA and 13.9x P/B. A premium to the sector — justified only if growth and returns hold.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
FY25 mix: API 46% / CDMO 28% / FDF 13% / Bio 13% (Bio→RoW field). +108% 1Y stock on CDMO re-rating.